Incuity Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 6 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.00 M
- Revenue Growth 287.74%
- Profit Growth 119.84%
- Ebitda 135.44%
- Net Worth 114.45%
- Total Assets 30.73%
About Incuity Pharma
Incuity Pharma Private Limited (IPPL) is a Private Limited Indian Non-Government Company incorporated in India on 31 October 2018 (Six years and three months 4 days old ). Its registered office is in Panchkula, Haryana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹4.00 M.
Rohit Jangwan and Ankit serve as directors at the Company.
Company Details
-
Location
Panchkula, Haryana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74999HR2018PTC076730
-
Company No.
076730
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
31 Oct 2018
-
Date of AGM
29 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Incuity Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rohit Jangwan
|
Director | 31-Oct-2018 | Current |
|
Ankit
|
Director | 11-Jan-2019 | Current |
Financial Performance of Incuity Pharma.
Incuity Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 287.74% increase. The company also saw a substantial improvement in profitability, with a 119.84% increase in profit. The company's net worth Soared by an impressive increase of 114.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Incuity Pharma?
Unlock access to Incuity Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Cohiba Pharmaceuticals Private LimitedRohit Jangwan is a mutual person
-
Innovative Lifesciences Private LimitedRohit Jangwan and Ankit are mutual person
Charges (Loans)
₹4.00 M
₹0
Charges Breakdown by Lending Institutions
- Indian Overseas Bank : 0.40 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Nov 2021 | Indian Overseas Bank | ₹4.00 M | Open |
How Many Employees Work at Incuity Pharma?
Unlock and access historical data on people associated with Incuity Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Incuity Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Incuity Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
